Cart
sales@molnova.com
RP-5063
CAS No. 1239729-06-6
RP-5063( RP5063 )
Catalog No. M10967 CAS No. 1239729-06-6
RP-5063 (Brilaroxazine) is a multimodal dopamine and serotonin modulator with partial agonist activity at DA D2, D3, D4, 5-HT1A, and 5-HT2ARs, and antagonist activity at 5-HT2B, 5-HT6 and 5-HT7Rs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 282 | In Stock |
|
| 5MG | 250 | In Stock |
|
| 10MG | 407 | In Stock |
|
| 25MG | 700 | In Stock |
|
| 50MG | 986 | In Stock |
|
| 100MG | 1349 | In Stock |
|
| 200MG | 1795 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRP-5063
-
NoteResearch use only, not for human use.
-
Brief DescriptionRP-5063 (Brilaroxazine) is a multimodal dopamine and serotonin modulator with partial agonist activity at DA D2, D3, D4, 5-HT1A, and 5-HT2ARs, and antagonist activity at 5-HT2B, 5-HT6 and 5-HT7Rs.
-
DescriptionRP-5063 (Brilaroxazine) is a multimodal dopamine and serotonin modulator with partial agonist activity at DA D2, D3, D4, 5-HT1A, and 5-HT2ARs, and antagonist activity at 5-HT2B, 5-HT6 and 5-HT7Rs; produces dose-dependent reductions in pulmonary blood vessel wall thickness and proportion of muscular vessels, blocks MCT-induced increases in the plasma cytokines TNFα, IL-1β, and IL-6 in vivo; prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats; improves declarative memory and psychosis in mouse models of schizophrenia.Schizophrenia Phase 2 Clinical.
-
In Vitro——
-
In VivoBrilaroxazine (oral gavage; 10 mg/kg; twice daily; 28 days) limits the functional and structural effects of pulmonary arterial hypertension (PAH), with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes. Animal Model:SD-rats Dosage:10 mg/kg Administration:Oral gavage; twice daily; 28 days Result:Had the efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH.
-
SynonymsRP5063
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine Receptor
-
Research AreaNeurological Disease
-
IndicationSchizophrenia
Chemical Information
-
CAS Number1239729-06-6
-
Formula Weight450.36
-
Molecular FormulaC22H25Cl2N3O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (222.04 mM)
-
SMILESC1CN(CCN1CCCCOC2=CC3=C(C=C2)OCC(=O)N3)C4=C(C(=CC=C4)Cl)Cl
-
Chemical Name6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bhat L, et al. Eur J Pharmacol. 2017 Sep 5;810:83-91.
2. Rajagopal L, et al. Behav Brain Res. 2017 Aug 14;332:180-199.
3. Bhat L, et al. Eur J Pharmacol. 2017 Sep 5;810:92-99.
molnova catalog
related products
-
PD-168077 maleate
PD-168077 maleate is a selective agonist of dopamine D4 receptor(Ki : 9 nM)PD-168077, a selective D4 dopamine receptor agonist, injected into the paraventricular nucleus of the hypothalamus on penile erection was studied in male rats.?PD-168077 (1-200 ng) induced penile erection in a dose-dependent manner.?
-
Ordopidine
Ordopidine (ACR325) is a dopaminergic stabilizer that suppresses psychostimulant-induced hyperactivity disorder and stimulates behavior during inactivity.
-
rac-Rotigotine hydro...
A non-selective agonist of the dopamine D3 receptor (Ki=0.71 nM); has 10-fold selectivity for the D3 receptor over the D2, D4, and D5 receptors and 100-fold selectivity for the D3 receptor over the D1 receptor.
